PharmacyChecker Blog

Helping Americans Get The Truth About Prescription Drug Savings
Published by:

Rep. Schakowsky (D-IL) Gets an A+ on Drug Prices in Congressional Report Card

This post was originally published on Prescription Justice.

The highest score in the Prescription Justice Congressional Report Card on Drug Prices – 100 – goes to Representative Jan Schakowsky (D-IL), with a grade of A+. The only other A+ in the House goes to Rep. Perter Welch (D-VT), who landed a score of 99.5.

In simple terms: Rep. Schakowsky gets the high score because she was incredibly committed, active and vocal about lowering drug prices – and barely takes money from drug companies: just over $1000. If all members of Congress hopped on the drug price lowering bandwagon just like Rep. Schakowsky, the crisis of high drug prices in America would end.


Trump administration surrogate says you can buy cheaper meds from Canada

A surrogate for the Trump campaign, Katy Talento, stated in an interview with Elisabeth Rosenthal, Editor-in-Chief, Kaiser Health News, that personal drug importation is allowed as a means for Americans to afford prescription drugs. I bring this up to make two points:

One, to remind the reader about the legal basis for the non-enforcement policy.

Two, to point out that during the Trump administration, the FDA has actually increased the numbers of prescription drug orders from other countries that it seizes, flouting the non-enforcement policy.

Ms. Talento’s remarks came in the form of an answer to a question that Ms. Rosenthal asked on behalf of Mike from Louisiana. Mike stated that he and his wife get their meds from Canada because they cost 50-75% less. Trump has been raging about drug prices for four years, but when are they going to see savings on their U.S. pharmacy shelves? Start at minute 42:00 in the video below.


No Description

The key remark by Ms. Talento is as follows:


HHS Insulin Import RFP Misinterprets the Law: Reimportation vs Importation

There is no end to my fascination over the new authorized pathways for wholesale and personal importation of lower cost drugs from Canada and many other counties. Last week, I wrote about the request for proposals from HHS on personal drug importation; the week prior, about the certification of Section 804 for wholesale imports from Canada. Today, I’m going to get very, very nerdy about the new Request For Proposals issued to allow for the reimportation of insulin. I am not sure the government could get more obtuse than this in trying to pretend to help people with importation while making it exceedingly difficult and limited.

Unlike the final rule on Section 804 of the FDCA and personal importation pathway opportunities also under Section 804, the Insulin RFP relates to Section 801(d)(1)(2) of the FDCA (21 U.S.C. 381). Veterans of this policy debate would recall this as the statute banning reimportation of prescription drugs. Notice the “re” is underlined.

From 1988 until 2017, Section 801(d), called “Reimportation,” banned any importation of a drug manufactured in the U.S., then exported, from being imported – or reimported – except by the manufacturer of that drug. The only exception, found in 801(d)(2), was if the Secretary declared that importing a drug is “required for emergency medical care.”


FDA opens door to expressly permit personal drug importation, and yet…

Americans have been personally importing medications for decades. In most cases, the reason is that the same drugs sold in the U.S. are much cheaper elsewhere. According to a recent JAMA article, about 2.3 million Americans import drugs to save money each year. The Kaiser Family Foundation pegged the number at about 20 million, total. This, despite the fact that, under most circumstances, such imports are prohibited. As explained below, under an executive order and a request for proposals by the U.S. Department of Health and Human Services and Food and Drug Administration (HHS/FDA), the door has been opened to formally allow personal drug importation, but the proposed parameters of the RFP ignore greater opportunities, savings and the law itself.

First, wholesale importation of lower cost drugs from Canada is now lawful. That is pursuant to Section 804 of the Food, Drug and Cosmetic Act. Such wholesale importations had been prohibited because the HHS Secretary had yet to certify that the importation would cause no additional public health risk and result in substantial savings for Americans. That certification, as required in Part L of Section 804, was provided by Sectary Azar last week.


Hoping Trump’s Florida Drug Importation Politics Helps Patients Under Biden

Well, as I was writing this post about the politics of importation, the FDA published its final rule on drug importation. Find it here: Section 804 Final Rule. It’s 179 pages so I haven’t had time to read it all yet.

As a quick reminder, pursuant to Section 804 of the Food, Drug and Cosmetic Act, the FDA issued a proposed new rule to allow wholesale imports of lower-cost drugs from Canada, subject to many conditions and excluding expensive biologics. Phillip Galewitz of Kaiser Health News asks if this is an “election gift for Florida” reporting that Florida will be the first state granted approval to import by the FDA. This is not surprising. Florida has an exceptionally large number of retired, older Americans who are unhappy about the cost of prescription drugs and 29 electoral college votes that Trump cannot afford to lose.


Explaining Rep. Pelosi’s F Grade on Drug Prices

Originally published on

Prescription Justice has graded all members of Congress in a drug prices report card. Some people are dismayed that Speaker Nancy Pelosi received an F. After all, didn’t she roll-out and shepherd H.R. 3, the Elijah Cummings Lower Drug Costs Now Act, through the House and vociferously called for its passage on the House floor, as read on the Speaker’s website. So, what happened to her grade? A lot of Rep. Pelosi’s F has to do with her role as Speaker and how it differs from all other legislators.

I admire Speaker Pelosi for many – even most – positions she’s taken and advanced throughout her career – including her work to pass H.R. 3. Not surprisingly, I’m a Democrat! But that cannot change the math of our system of grading.  

Due to the methodology and quantitative factors used to create the report card, even a vocal advocate like Rep. Pelosi, can get an F. You see Prescription Justice grades objectively on the following factors: 1) votes; 2) bill sponsorships/co-sponsorships, 3) campaign contributions from drug companies; and 3) policy positions articulated on member’s websites.